Arthur Gutierrez-Hartmann

List of Publications by Year
in descending order

81 papers	3,183 citations	201674 27 h-index	161849 54 g-index
81 all docs	81 docs citations	81 times ranked	3471 citing authors

#	Article	IF	Citations
1	Ets transcription factors: nuclear effectors of the Rasâ€“MAP-kinase signaling pathway. Trends in Biochemical Sciences, 1998, 23, 213-216.	7.5	473
2	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics, 2015, 47, 535-538.	21.4	274
3	Functional Interaction of c-Ets-1 and GHF-1/Pit-1 Mediates Ras Activation of Pituitary-Specific Gene Expression: Mapping of the Essential c-Ets-1 Domain. Molecular and Cellular Biology, 1995, 15, 2849-2857.	2.3	117
4	ETS transcription factors in endocrine systems. Trends in Endocrinology and Metabolism, 2007, 18, 150-158.	7.1	116
5	Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 522-543.	5.2	113
6	Lipoprotein Lipase Gene Expression in Rat Adipocytes Is Regulated by Isoproterenol and Insulin through Different Mechanisms. Molecular Endocrinology, 1990, 4, 1416-1422.	3.7	108
7	Interaction of Ets-1 and the POU-Homeodomain Protein GHF-1/Pit-1 Reconstitutes Pituitary-Specific Gene Expression. Molecular and Cellular Biology, 1997, 17, 1065-1074.	2.3	105
8	Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene, 1997, 14, 899-913.	5.9	95
9	A Multifunctional Prokaryotic Protein Expression System: Overproduction, Affinity Purification, and Selective Detection. DNA and Cell Biology, 1993, 12, 441-453.	1.9	92
10	MicroRNAs Regulate Pituitary Development, and MicroRNA 26b Specifically Targets Lymphoid Enhancer Factor 1 (Lef-1), Which Modulates Pituitary Transcription Factor 1 (Pit-1) Expression. Journal of Biological Chemistry, 2010, 285, 34718-34728.	3.4	85
11	Selective transcription and DNase I protection of the rat prolactin gene by GH3 pituitary cell-free extracts.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5211-5215.	7.1	82
12	ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget, 2017, 8, 16951-16963.	1.8	82
13	Combination of osteoinductive bone proteins differentiates mesenchymal C3H/10T1/2 cells specifically to the cartilage lineage. Journal of Cellular Biochemistry, 1997, 65, 325-339.	2.6	78
14	GHF-1/Pit-1 Functions as a Cell-specific Integrator of Ras Signaling by Targeting the Ras Pathway to a Composite Ets-1/GHF-1 Response Element. Journal of Biological Chemistry, 1996, 271, 24639-24648.	3.4	56
15	ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene, 2004, 23, 1766-1779.	5.9	56
16	The ETS Transcription Factor ESE-1 Transforms MCF-12A Human Mammary Epithelial Cells via a Novel Cytoplasmic Mechanism. Molecular and Cellular Biology, 2004, 24, 5548-5564.	2.3	54
17	The Pit-1 Homeodomain and Î²-Domain Interact with Ets-1 and Modulate Synergistic Activation of the Rat Prolactin Promoter. Journal of Biological Chemistry, 2000, 275, 3100-3106.	3.4	50
18	Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Molecular Cancer, 2011, 10, 75.	19.2	49

#	Article	IF	Citations
19	The Epithelial-Specific ETS Transcription Factor ESX/ESE-1/Elf-3 Modulates Breast Cancer-Associated Gene Expression. DNA and Cell Biology, 2003, 22, 79-94.	1.9	45
20	Ets transcription factors in intestinal morphogenesis, homeostasis and disease. Histology and Histopathology, 2008, 23, 1417-24.	0.7	39
21	Functional Components of Fibroblast Growth Factor (FGF) Signal Transduction in Pituitary Cells. Journal of Biological Chemistry, 1997, 272, 30852-30859.	3.4	37
22	Protein Factors in Thyrotropic Tumor Nuclear Extracts Bind to a Region of the Mouse Thyrotropin Î²-Subunit Promoter Essential for Expression in Thyrotropes. Molecular Endocrinology, 1990, 4, 1897-1904.	3.7	33
23	Structure-Function Analysis of the Rat Prolactin Promoter: Phasing Requirements of Proximal Cell-Specific Elements. Molecular Endocrinology, 1991, 5, 836-843.	3.7	32
24	Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific. Molecular and Cellular Endocrinology, 2018, 463, 87-96.	3.2	32
25	Transcriptional Control of the Cell Cycle in Mammary Gland Development and Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2004, 9, 39-53.	2.7	31
26	Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12657-12662.	7.1	29
27	Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition. Thyroid, 2009, 19, 825-835.	4.5	29
28	Ras mediates Src but not epidermal growth factor-receptor tyrosine kinase signaling pathways in GH4 neuroendocrine cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8612-8616.	7.1	27
29	The Pit-1Î² Domain Dictates Active Repression and Alteration of Histone Acetylation of the Proximal Prolactin Promoter. Journal of Biological Chemistry, 2000, 275, 30977-30986.	3.4	27
30	Purification and Mass Spectrometric Identification of GA-binding Protein (GABP) as the Functional Pituitary Ets Factor Binding to the Basal Transcription Element of the Prolactin Promoter. Journal of Biological Chemistry, 2003, 278, 16863-16872.	3.4	27
31	Identification ofCis-Acting Promoter Elements Important for Expression of the Mouse Glycoprotein Hormone Î±-Subunit Gene in Thyrotropes. Molecular Endocrinology, 1990, 4, 766-772.	3.7	26
32	Human Cart-1: Structural Organization, Chromosomal Localization, and Functional Analysis of a Cartilage-Specific Homeodomain cDNA. DNA and Cell Biology, 1996, 15, 531-541.	1.9	26
33	Reconstitution of the Protein Kinase A Response of the Rat Prolactin Promoter: Differential Effects of Distinct Pit-1 Isoforms and Functional Interaction with Oct-1. Molecular Endocrinology, 1999, 13, 228-238.	3.7	26
34	Transcription of two classes of rat growth hormone gene-associated repetitive DNA: differences in activity and effects of tandem repeat structure. Nucleic Acids Research, 1984, 12, 7153-7173.	14.5	25
35	High Efficiency Molecular Delivery with Sequential Low-Energy Sonoporation Bursts. Theranostics, 2015, 5, 1419-1427.	10.0	25
36	Role of Specific Protein Kinase C Isozymes in Mediating Epidermal Growth Factor, Thyrotropin-Releasing Hormone, and Phorbol Ester Regulation of the Rat Prolactin Promoter in GH4/GH4C1 Pituitary Cells. Molecular Endocrinology, 2002, 16, 2840-2852.	3.7	24

#	Article	IF	Citations
37	Identification of Thyrotroph-Specific Factors andCis-Acting Sequences of the Murine ThyrotropinÎ² Subunit Gene. Molecular Endocrinology, 1989, 3, 1037-1045.	3.7	23
38	Insulin activation of rat prolactin promoter activity. Molecular and Cellular Endocrinology, 1991, 78, 55-60.	3.2	23
39	A 26-Amino Acid Insertion Domain Defines a Functional Transcription Switch Motif in Pit-1Î². Journal of Biological Chemistry, 1996, 271, 28925-28932.	3.4	23
40	Epidermal Growth Factor and Ras Regulate Gene Expression in GH4 Pituitary Cells by Separate, Antagonistic Signal Transduction Pathways. Molecular and Cellular Biology, 1995, 15, 6777-6784.	2.3	22
41	The c-Jun Î´-Domain Inhibits Neuroendocrine Promoter Activity in a DNA Sequence- and Pituitary-specific Manner. Journal of Biological Chemistry, 1996, 271, 17139-17146.	3.4	22
42	CEBPD Suppresses Prolactin Expression and Prolactinoma Cell Proliferation. Molecular Endocrinology, 2011, 25, 1880-1891.	3.7	21
43	Persistent ERK/MAPK Activation Promotes Lactotrope Differentiation and Diminishes Tumorigenic Phenotype. Molecular Endocrinology, 2014, 28, 1999-2011.	3.7	21
44	Lipopolysaccharide and Raf-1 Kinase Regulate Secretory Interleukin-1 Receptor Antagonist Gene Expression by Mutually Antagonistic Mechanisms. Molecular and Cellular Biology, 1997, 17, 1118-1128.	2.3	20
45	Ras Signaling and Transcriptional Synergy at a Flexible Ets-1/Pit-1 Composite DNA Element Is Defined by the Assembly of Selective Activation Domains. Journal of Biological Chemistry, 2003, 278, 39684-39696.	3.4	20
46	The 26-Amino Acid ÃŸ-Motif of the Pit-1ÃŸ Transcription Factor Is a Dominant and Independent Repressor Domain. Molecular Endocrinology, 2009, 23, 1371-1384.	3.7	20
47	Control of MicroRNA-21 Expression in Colorectal Cancer Cells by Oncogenic Epidermal Growth Factor/Ras Signaling and Ets Transcription Factors. DNA and Cell Biology, 2012, 31, 1403-1411.	1.9	20
48	Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Research, 2001, 29, 1251-1260.	14.5	19
49	Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Molecular Cancer, 2011, 10, 103.	19.2	19
50	Targeted Intracellular Delivery of Trastuzumab Using Designer Phage Lambda Nanoparticles Alters Cellular Programs in Human Breast Cancer Cells. ACS Nano, 2021, 15, 11789-11805.	14.6	18
51	The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology, 2018, 159, 2421-2434.	2.8	17
52	Helix-loop-helix proteins are present and differentially expressed in different cell lines from the anterior pituitary. Molecular and Cellular Endocrinology, 1993, 96, 167-176.	3.2	16
53	Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells. BMC Cancer, 2010, 10, 373.	2.6	16
54	A Pit-1 Threonine 220 Phosphomimic Reduces Binding to Monomeric DNA Sites to Inhibit Ras and Estrogen Stimulation of the Prolactin Gene Promoter. Molecular Endocrinology, 2010, 24, 91-103.	3.7	15

#	Article	IF	Citations
55	Signaling Pathways Regulating Pituitary Lactotrope Homeostasis and Tumorigenesis. Advances in Experimental Medicine and Biology, 2015, 846, 37-59.	1.6	15
56	Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer. Nanotheranostics, 2019, 3, 212-222.	5.2	15
57	ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight, 2020, 5, .	5.0	15
58	ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells. Oncotarget, 2017, 8, 69622-69640.	1.8	14
59	Pit-1Î² reduces transcription and CREB-binding protein recruitment in a DNA context-dependent manner. Journal of Endocrinology, 2005, 185, 173-185.	2.6	12
60	Differential Utilization of Transcription Activation Subdomains by Distinct Coactivators Regulates Pit-1 Basal and Ras Responsiveness. Molecular Endocrinology, 2007, 21, 172-185.	3.7	12
61	Ets Transcription Factors Control Epithelial Maturation and Transit and Crypt-Villus Morphogenesis in the Mammalian Intestine. American Journal of Pathology, 2009, 174, 1280-1290.	3.8	12
62	ESE-1 is Required to Maintain the Transformed Phenotype of MCF-7 and ZR-75-1 Human Breast Cancer Cells. The Open Cancer Journal, 2010, 3, 77-88.	0.2	12
63	Transforming Growth Factor-beta1 Inhibits Rat Prolactin Promoter Activity in GH4Neuroendocrine Cells. DNA and Cell Biology, 1999, 18, 863-873.	1.9	10
64	LZ-FYVE: A Novel Developmental Stage-Specific Leucine Zipper, FYVE-Finger Protein. DNA and Cell Biology, 2001, 20, 403-412.	1.9	10
65	Editorial: PRL-Releasing Peptide Stimulation of PRL Gene Transcriptionâ€"Enter AKT. Endocrinology, 2002, 143, 11-12.	2.8	9
66	Reconstitution of the Protein Kinase A Response of the Rat Prolactin Promoter: Differential Effects of Distinct Pit-1 Isoforms and Functional Interaction with Oct-1. Molecular Endocrinology, 1999, 13, 228-238.	3.7	8
67	ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells. Anticancer Research, 2017, 37, 6583-6591.	1.1	8
68	Selective Repression of Rat Prolactin Gene by Stable Expression of Dominant-Negative Ets in GH4 Pituitary Cells. Endocrine, 2003, 20, 3-12.	2.2	7
69	ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients. Breast Cancer Research and Treatment, 2020, 182, 601-612.	2.5	7
70	Stable accumulation of a rat truncated repeat transcript in Xenopus oocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 3106-3110.	7.1	6
71	Activation of the Murine Thyrotropin Î²-Subunit Promoter by GH4Rat Pituitary Cell-Free Extracts. Molecular Endocrinology, 1990, 4, 1887-1896.	3.7	6
72	Elucidation of Homeoprotein Cartâ€1 Function during In Vitro Chondrogenesis of C3H10T1/2 Micromass Cultures. Annals of the New York Academy of Sciences, 1996, 785, 206-208.	3.8	6

#	Article	IF	Citations
73	The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice. BMC Cancer, 2009, 9, 197.	2.6	5
74	Differential Ability of Various Plasmid DNAs to Sequester Inhibitors of RNA Polymerase III Transcription. DNA and Cell Biology, 1987, 6, 231-237.	5.2	4
75	Cell-specific expression of transfected brain identifier repetitive DNAs. Nucleic Acids Research, 1988, 16, 3963-3976.	14.5	4
76	The vanishing physician-scientist?. Journal of Clinical Investigation, 2010, 120, 1367-1367.	8.2	4
77	Structural and Functional Analysis of the Differential Effects of c-Jun and v-Jun on Prolactin Gene Expression. Molecular Endocrinology, 2004, 18, 2479-2490.	3.7	1
78	Ets Transcription Factors. , 2000, , 39-65.		1
79	Pituitary somatolactotropes evade an oncogenic response to Ras. Molecular and Cellular Endocrinology, 2018, 476, 165-172.	3.2	0
80	Abstract 3298: Elf3 as negative regulation for epithelial-mesenchymal transition in ovarian cancer. , 2010, , .		0
81	Abstract 1971: ESE-1 controls transformation properties in HER2+ breast cancer cells, and predicts poor prognostic status and survival in breast cancer patients. , 2015, , .		0